Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
 |
AIDS TREATMENT NEWS Issue #382, August 9, 2002
John S. James
Note: Web sites often get reorganized, so some of these links may not work when you try them. In that case, go to the home page of the site (usually the part of the address through the .com or .org), and look for the reports from there.
The annotations in brackets below are our own.
* Medscape [information for medical professionals and patients] http://www.medscape.com/viewprogram/1980 also see http://www.medscape.com/pages/editorial/newsbeats/aids
* Kaiser Family Foundation [general conference news widely syndicated on other sites] http://www.kaisernetwork.org/aids2002/
* Health & Development Networks [important international coverage] http://www.hdnet.org/home2.htm
* The Body [focus on new drugs and other medical news] http://www.thebody.com/confs/aids2002/aids2002.html
* International Association of Physicians in AIDS Care (IAPAC), http://www.iapac.org/ [Choose IAPAC AIDScan for their daily newsletter on the conference.]
* HIV and Hepatitis.com [many news reports] http://www.hivandhepatitis.com
* National AIDS Treatment Advocacy Project [occasional medical articles, also strong on hepatitis] http://www.natap.org/
* For a short (6 pages single spaced) overview of the conference, focusing on medical information that will affect patient care over the next several years, see "A Roundup of Barcelona" by Pablo Tebas, available at: http://www.thebody.com/confs/aids2002/tebas10.html >From the Roundup: "The science -- at least the clinical part -- was very good this time, much better than in Durban or in Retrovirus this year. Major trials like ACTG 384, INITIO, Gilead 903, and the TORO trials were presented during the Barcelona conference. These trials will mark the next months if not years of HIV treatment.
020809
ATN38202
Copyright © 2002 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .